254 related articles for article (PubMed ID: 29474866)
1. Targeted proteomic analysis of cognitive dysfunction in remitted major depressive disorder: Opportunities of multi-omics approaches towards predictive, preventive, and personalized psychiatry.
Schubert KO; Stacey D; Arentz G; Clark SR; Air T; Hoffmann P; Baune BT
J Proteomics; 2018 Sep; 188():63-70. PubMed ID: 29474866
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.
Amare AT; Schubert KO; Baune BT
EPMA J; 2017 Sep; 8(3):211-227. PubMed ID: 29021832
[TBL] [Abstract][Full Text] [Related]
3. Advancing translational research and precision medicine with targeted proteomics.
Uzozie AC; Aebersold R
J Proteomics; 2018 Oct; 189():1-10. PubMed ID: 29476807
[TBL] [Abstract][Full Text] [Related]
4. High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis.
Lin L; Zheng J; Yu Q; Chen W; Xing J; Chen C; Tian R
J Proteomics; 2018 Mar; 174():9-16. PubMed ID: 29278786
[TBL] [Abstract][Full Text] [Related]
5. A practical data processing workflow for multi-OMICS projects.
Kohl M; Megger DA; Trippler M; Meckel H; Ahrens M; Bracht T; Weber F; Hoffmann AC; Baba HA; Sitek B; Schlaak JF; Meyer HE; Stephan C; Eisenacher M
Biochim Biophys Acta; 2014 Jan; 1844(1 Pt A):52-62. PubMed ID: 23501674
[TBL] [Abstract][Full Text] [Related]
6. The role of cognitive impairment in psychosocial functioning in remitted depression.
Knight MJ; Air T; Baune BT
J Affect Disord; 2018 Aug; 235():129-134. PubMed ID: 29655074
[TBL] [Abstract][Full Text] [Related]
7. Immune gene co-expression signatures implicated in occurence and persistence of cognitive dysfunction in depression.
Zang JCS; Hohoff C; Van Assche E; Lange P; Kraft M; Sandmann S; Varghese J; Jörgens S; Knight MJ; Baune BT
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Dec; 127():110826. PubMed ID: 37451594
[TBL] [Abstract][Full Text] [Related]
8. Co-expression network analysis of peripheral blood transcriptome identifies dysregulated protein processing in endoplasmic reticulum and immune response in recurrent MDD in older adults.
Ciobanu LG; Sachdev PS; Trollor JN; Reppermund S; Thalamuthu A; Mather KA; Cohen-Woods S; Stacey D; Toben C; Schubert KO; Baune BT
J Psychiatr Res; 2018 Dec; 107():19-27. PubMed ID: 30312913
[TBL] [Abstract][Full Text] [Related]
9. Similar profiles of cognitive domain deficits between medication-naïve patients with bipolar II depression and those with major depressive disorder.
Liu T; Zhong S; Wang B; Liao X; Lai S; Jia Y
J Affect Disord; 2019 Jan; 243():55-61. PubMed ID: 30227315
[TBL] [Abstract][Full Text] [Related]
10. Discovery of serum protein biomarkers in drug-free patients with major depressive disorder.
Lee MY; Kim EY; Kim SH; Cho KC; Ha K; Kim KP; Ahn YM
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():60-8. PubMed ID: 27105922
[TBL] [Abstract][Full Text] [Related]
11. Pathway-Informed Discovery and Targeted Proteomic Workflows Using Mass Spectrometry.
Chu CS; Miller CA; Gieschen A; Fischer SM
Methods Mol Biol; 2017; 1550():199-221. PubMed ID: 28188532
[TBL] [Abstract][Full Text] [Related]
12. Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis.
Ren J; Zhao G; Sun X; Liu H; Jiang P; Chen J; Wu Z; Peng D; Fang Y; Zhang C
Psychoneuroendocrinology; 2017 Dec; 86():17-24. PubMed ID: 28910601
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers in major depressive disorder: the role of mass spectrometry.
Woods AG; Iosifescu DV; Darie CC
Adv Exp Med Biol; 2014; 806():545-60. PubMed ID: 24952202
[TBL] [Abstract][Full Text] [Related]
14. Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders.
Preece RL; Han SYS; Bahn S
Expert Rev Proteomics; 2018 Apr; 15(4):325-340. PubMed ID: 29466886
[TBL] [Abstract][Full Text] [Related]
15. An ethnographic study of the effects of cognitive symptoms in patients with major depressive disorder: the IMPACT study.
Ebert B; Miskowiak K; Kloster M; Johansen J; Eckholm C; Wærner T; Holme M; Bruun LM
BMC Psychiatry; 2017 Nov; 17(1):370. PubMed ID: 29157207
[TBL] [Abstract][Full Text] [Related]
16. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
Ali M; Khan SA; Wennerberg K; Aittokallio T
Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
[TBL] [Abstract][Full Text] [Related]
17. Protein Biomarkers in Major Depressive Disorder: An Update.
Woods AG; Wormwood KL; Iosifescu DV; Murrough J; Darie CC
Adv Exp Med Biol; 2019; 1140():585-600. PubMed ID: 31347073
[TBL] [Abstract][Full Text] [Related]
18. Cognitive Deficits in the THINC-Integrated Tool (THINC-it) Are Associated With Psychosocial Dysfunction in Patients With Major Depressive Disorder.
Knight MJ; Fourrier C; Lyrtzis E; Aboustate N; Sampson E; Hori H; Mills NT; Baune BT
J Clin Psychiatry; 2018 Nov; 80(1):. PubMed ID: 30549482
[TBL] [Abstract][Full Text] [Related]
19. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder.
Cha DS; Carmona NE; Subramaniapillai M; Mansur RB; Lee Y; Hon Lee J; Lee J; Rosenblat JD; Shekotikhina M; Park C; Rong C; Greer TL; Lam R; Baune BT; Harrison J; McIntyre RS
J Affect Disord; 2017 Nov; 222():14-20. PubMed ID: 28667888
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
